Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

Researchers create new drug to reduce inflammation of donor organ after transplantation

Researchers create new drug to reduce inflammation of donor organ after transplantation

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers develop potential antibody therapy for Sudan ebolavirus

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

OMRF receives $14.5 million grant from NIH to continue research on anthrax

OMRF receives $14.5 million grant from NIH to continue research on anthrax

Choroidal consequences differ between anti-VEGF therapies

Choroidal consequences differ between anti-VEGF therapies

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Natural killer cells can be used to combat acute lymphoblastic leukemia

Natural killer cells can be used to combat acute lymphoblastic leukemia

Anti-EphA3 antibody has anti-tumour effects against solid cancers

Anti-EphA3 antibody has anti-tumour effects against solid cancers

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Researchers plan to develop vaccine into a type of antibody serum therapy

Researchers plan to develop vaccine into a type of antibody serum therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.